IL6 and rheumatic disorder: The participants with rheumatic disease were under pharmacological treatment, including: hydroxychloroquine (9 patients), hydroxychloroquine monotherapy (5), tumor necrosis factor (TNF) inhibitor (7), interleukin 6 (IL-6) receptor inhibitor (1), belimumab (2), rituximab (3), interleukin 12/interleukin 23 (IL-12/IL-23) inhibitor (2), abatacept (1), tofacitinib (3), methotrexate (9), leflunomide (4), mycophenolate mofetil (3) and prednisone (5).